摘要
目的 评价美罗培南对晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）合并呼吸机相关性肺炎（ventilatorassociated pneumonia,VAP）的临床疗效。方法 选取2013年6月~2015年10月在丽水市人民医院ICU救治的142例NSCLC合并VAP的患者随机分为研究组和对照组,各71例。2组均给予常规治疗,研究组在常规治疗基础上给予美罗培南,疗程2周。比较2组患者的临床疗效、细菌清除率和临床症状改善情况。结果 研究组临床总有效率显著高于对照组（91.5%vs.71.8%;χ2=6.884,P〈0.05）。研究组细菌清除率显著高于对照组（69.0%vs.49.3%;χ2=5.713,P〈0.05）。研究组的咳嗽消失时间、发热消失时间和湿罗音消失时间都明显快于对照组,入住ICU时间短于对照组（P〈0.05）。结论 在传统治疗基础上给予美罗培南治疗NSCLC合并VAP,能明显提高临床疗效、改善临床症状、提高细菌清除率。
Objective To evaluate the effect of meropenem in the treatment of ventilator-associated pneumonia （VAP） in advanced non-small cell lung cancer （NSCLC） patients. Methods 142 patients with NSCLC complicated with VAP from June 2013 to October 2015 in our hospital were randomly divided into research group and control group, 71 cases in each group. Both groups received conventional treatment, and the research group received meropenem on the basis of conbeutional group. All treated for 2 weeks. The curative effect, the bacteria clearance rate and symptoms improving status were compared betweent two groups. Results The total effective rate in research group was significantly higher than that in control group （91.5% vs. 71.8% ;X2 = 6. 884, P 〈 0. 05 ）. The bacterial clearance rate in research group was significantly higher than that in control group （69.0% vs. 49.3 % ; X2 = 5. 7 13, P 〈 0. 05 ）. The disappearance time of cough, fever and moist rale in research group were significantly faster than those in control group, and the ICU admission time in research group was shorter than ,that in control group （ P 〈 0. 05 ）. Conclusion Meropenem could obviously improve the clinical curative effect, clinical symptoms and bacterial clearance rate in the treatment of VAP in NSCLC patients on the basis of conventional treatment.
出处
《中国生化药物杂志》
CAS
2016年第2期62-64,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
浙江省医药卫生科学研究基金(2012KYA023)
关键词
美罗培南
非小细胞肺癌
呼吸机相关性肺炎
机械通气
meropenem
non-small cell lung cancer
ventilator-associated pneumonia
mechanical ventilation
